Immunomedics, Inc. (NASDAQ:IMMU) Director David M. Goldenberg sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $17.50, for a total transaction of $350,000.00. Following the completion of the transaction, the director now owns 1,774,285 shares of the company’s stock, valued at $31,049,987.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Immunomedics, Inc. (IMMU) traded down $0.01 during midday trading on Monday, hitting $17.29. 1,775,357 shares of the stock were exchanged, compared to its average volume of 2,020,000. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $2,630.00, a price-to-earnings ratio of -9.30 and a beta of 1.48. Immunomedics, Inc. has a 1-year low of $5.00 and a 1-year high of $18.93.
Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.09). The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.90 million. equities research analysts predict that Immunomedics, Inc. will post -0.96 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. lifted its position in shares of Immunomedics by 11.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,473 shares in the last quarter. Calton & Associates Inc. purchased a new stake in shares of Immunomedics in the fourth quarter worth approximately $135,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Immunomedics in the fourth quarter worth approximately $193,000. Sapphire Star Partners LP purchased a new stake in shares of Immunomedics in the fourth quarter worth approximately $323,000. Finally, SG Americas Securities LLC lifted its position in shares of Immunomedics by 27.2% in the third quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 5,631 shares in the last quarter. 74.52% of the stock is owned by institutional investors and hedge funds.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.